If you are long MNTA, you probably do not want to read this article from the WSJ today: (dr.vinmantoo and perryfinker please take note as you are the only ones that post here)
Several high-profile projects to create so-called biosimilar drugs have faltered in recent months. Merck MRK +0.93% & Co. dissolved a dedicated biosimilar unit last year and in December retreated from a plan to copy arthritis treatment Enbrel after maker Amgen Inc. AMGN +1.58% gained a new patent. Last fall, Samsung Electronics Co.'s 005930.SE 0.00% biosimilar unit suspended trials for a version of the cancer drug Rituxan, and generic-drug maker Teva Pharmaceutical Industries Ltd. TEVA +0.00% halted its own Rituxan push.
Merck said last Wednesday it was essentially starting over, forging a new biosimilar partnership with Samsung. "There has been a little bit of volatility" in biosimilar efforts, said Richard Murray, vice president of Merck's vaccines and biologics unit. Merck won't abandon internal biosimilar projects, Dr. Murray said, but its portfolio is shifting away from the copies.
Samsung declined to comment and Teva didn't respond to requests for comment.
Such retrenchments dash hopes that a wave of cheaper biologic alternatives will emerge any time soon, even as patents begin to expire on complex biotech drugs, which can cost thousands of dollars per dose. Prices usually plummet when conventional drugs come off patent and generic makers swoop in. For example, Pfizer Inc.'s PFE +1.02% cholesterol fighter Lipitor sold for a median price of $3.36 per pill before losing patent protection in 2011; several months later, generic copies of the drug, atorvastatin, went for pennies.
I doubt any of these companies mentioned in the article have the ability to characterize complicated molecules that MNTA does. MNTA's patented and proven science gives them the ability to repeatedly offer biosimilars as soon patents expire.on the proprietary drugs .MNTA's success with their Lovenex biosimilar will be repeated on a succession of future efforts. Short term without a buyout the stocks has a modest upside with no imminent new products. Possibly the Supreme Court will reverse that rediculous "Safe Harbor" patent infringement decision. Long term this could have a substanial upside.